You searched for duvelisib - Page 4 of 6

ASH 2020: Dr. Davids Discusses Treatment Strategies for Chronic Lymphocytic Leukemia (CLL)

July 2, 2021

In this video, Dr. Matthew Davids, M.D., an Associate Professor of Medicine at Harvard Medical School and the Director of Clinical Research for Lymphoma at Dana-Farber Cancer Institute in Boston, discusses his views on treatment strategies of patients with chronic lymphocytic leukemia (CLL). This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.

ASH 2020: Dr. Paul Barr’s Update on the Combination of Umbralisib, Ublituximab, and Venetoclax for Treatment of Chronic Lymphocytic Leukemia (CLL)

April 23, 2021

ASH 2020: Dr. Paul Barr’s Update on the Combination of Umbralisib, Ublituximab, and Venetoclax for Treatment of Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Richard Furman on Selecting Chronic Lymphocytic Leukemia (CLL) Therapies During the COVID-19 Pandemic

March 21, 2021

ASH 2020: Dr. Richard Furman on selecting chronic lymphocytic leukemia (CLL) therapies during the COVID-19 pandemic

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

March 1, 2021

During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.

ASH 2020: Dr. Mato Discusses a Once Daily, Oral Triple Therapy Clinical Trial for Richter’s Transformation and De Novo Large B-Cell Lymphoma

January 17, 2021

This clinical trial introduces the concept of “synthetic lethality,” where multiple targeted agents are used at low dosages to block different pathways, and achieve the ability to kill cancer cells without the associated toxicities of using three drugs together at their usual dosages.

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

September 17, 2020

The methodologies for testing MRD are evolving and finding less than 1 in 10,000 cells by flow cytometry is today’s standard definition for undetectable minimal or measurable residual disease (uMRD). There is good reason to believe that the deeper levels achievable with next generation gene sequencing (NGS), capable of finding a single cancer cell in a million cells, may be even more valuable, especially with cellular therapies such as CAR-T and transplants.

ASH 2019: Dr. Furman Discusses Bruton’s Tyrosine Kinase Inhibitors Evolution

August 20, 2020

ASH 2019 Drs. Brian Koffman and Richard Furman discuss the effectiveness and tolerability of covalent irreversible BTK inhibitors such as acalabrutinib, ibrutinib, and zanubrutinib, as well as non-covalent, reversible (3rd generation) BTK inhibitors such as vecabrutinib, LOXO 305, and ArQule 561.

ASCO 2020 Top 12” #7: Tolerability and durable responses of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies

July 10, 2020

In short videos with accompanying text, Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, takes us through his “Top 12” abstracts from

ASH 2019: Dr. Pagel Discusses Intermittent Dosing of the PI3K Inhibitor ME401 in Chronic Lymphocytic Leukemia (CLL)

May 4, 2020

In our ASH 2019 interview with Dr. John Pagel, we learn that PI3 kinase inhibitors are potent medications that control CLL, but their widespread adoption has been slowed by their potential side effects.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: duvelisib – Page 4

ASH 2020: Dr. Davids Discusses Treatment Strategies for Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Paul Barr’s Update on the Combination of Umbralisib, Ublituximab, and Venetoclax for Treatment of Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Richard Furman on Selecting Chronic Lymphocytic Leukemia (CLL) Therapies During the COVID-19 Pandemic

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

ASH 2020: Dr. Mato Discusses a Once Daily, Oral Triple Therapy Clinical Trial for Richter’s Transformation and De Novo Large B-Cell Lymphoma

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

ASH 2019: Dr. Furman Discusses Bruton’s Tyrosine Kinase Inhibitors Evolution

ASCO 2020 Top 12” #7: Tolerability and durable responses of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies

ASH 2019: Dr. Pagel Discusses Intermittent Dosing of the PI3K Inhibitor ME401 in Chronic Lymphocytic Leukemia (CLL)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT